Source:http://linkedlifedata.com/resource/pubmed/id/15778488
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2005-6-8
|
| pubmed:abstractText |
Obliterative bronchiolitis (OB) is the major limitation for long-term survival of lung allograft recipients. We investigated the role of vascular endothelial growth factor (VEGF) in the development of OB in rat tracheal allografts. In nonimmunosuppressed allografts, VEGF mRNA and protein expression vanished in the epithelium and increased in smooth muscle cells and mononuclear inflammatory cells with progressive loss of epithelium and airway occlusion compared with syngeneic grafts. Intragraft VEGF overexpression by adenoviral transfer of a mouse VEGF(164) gene increased early epithelial cell proliferation and regeneration but increased microvascular remodeling and lymphangiogenesis and luminal occlusion by more than 50% compared with AdlacZ-treated allografts. Although VEGF receptor inhibition decreased early epithelial regeneration in noninfected allografts, it reduced microvascular remodeling, lymphangiogenesis, intragraft traffic of CD4(+) and CD8(+) T cells, and the degree of luminal occlusion. Simultaneous VEGF gene transfer and platelet-derived growth factor receptor inhibition with imatinib preserved respiratory epithelium and totally prevented luminal occlusion. In conclusion, our findings indicate that VEGF has a dual role in transplant OB. Our results suggest that VEGF may protect epithelial integrity. On the other hand, VEGF may enhance luminal occlusion by increasing the recruitment of mononuclear inflammatory cells with platelet-derived growth factor acting as a final effector molecule in this process.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
171
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1421-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15778488-Animals,
pubmed-meshheading:15778488-Biological Markers,
pubmed-meshheading:15778488-Biopsy, Needle,
pubmed-meshheading:15778488-Bronchiolitis Obliterans,
pubmed-meshheading:15778488-Disease Models, Animal,
pubmed-meshheading:15778488-Graft Rejection,
pubmed-meshheading:15778488-Graft Survival,
pubmed-meshheading:15778488-Immunohistochemistry,
pubmed-meshheading:15778488-Male,
pubmed-meshheading:15778488-Probability,
pubmed-meshheading:15778488-Rats,
pubmed-meshheading:15778488-Rats, Wistar,
pubmed-meshheading:15778488-Risk Assessment,
pubmed-meshheading:15778488-Sensitivity and Specificity,
pubmed-meshheading:15778488-Statistics, Nonparametric,
pubmed-meshheading:15778488-Tissue Transplantation,
pubmed-meshheading:15778488-Trachea,
pubmed-meshheading:15778488-Transplantation, Homologous,
pubmed-meshheading:15778488-Transplantation, Isogeneic,
pubmed-meshheading:15778488-Vascular Endothelial Growth Factor A
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis.
|
| pubmed:affiliation |
Cardiopulmonary Research Group, Transplantation Laboratory, University of Helsinki/Helsinki University Central Hospital, Helsinki, Finland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|